Final results from IMPROVE: a randomized, controlled, open-label, two-arm, cross-over phase IV study to determine patients’ preference for everolimus in combination with exemestane or capecitabine in combination with bevacizumab in advanced HR-positive, HER2-negative breast cancer

Peer Review reports

Original Submission
18 Oct 2019	Submitted	Original manuscript
10 Feb 2020	Reviewed	Reviewer Report - Marcus Schmidt
23 Feb 2020	Reviewed	Reviewer Report - Poonam Aggarwal
5 Mar 2020	Author responded	Author comments - Thomas Decker
10 Mar 2020	Author responded	Author comments - Thomas Decker
Resubmission - Version 2
5 Mar 2020	Submitted	Manuscript version 2
Publishing
12 Mar 2020	Editorially accepted
6 Apr 2020	Article published	10.1186/s12885-020-06747-y

Back to article page